Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program
April 29 2020 - 1:54PM
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical
company dedicated to the discovery, development and
commercialization of novel therapies for the treatment of cancer
and related conditions, today announced that an abstract for its
ongoing Phase II study of oral paclitaxel and encequidar (Oral
Paclitaxel; formerly known as Oraxol), for the treatment of
angiosarcoma, has been accepted for presentation in a poster
discussion session at the American Society of Clinical Oncology’s
(ASCO) upcoming ASCO20 Virtual Scientific Program, to be held from
May 29 to May 31, 2020.
Presentation details are as follows:
- Title: (Abstract 11517) A Phase II Study of
Oraxol in the Treatment of Unresectable Cutaneous Angiosarcoma
- Poster Session: Sarcoma
- Location: ASCO Virtual Scientific Program
This Phase II study is an ongoing, single arm study evaluating
the activity, safety and tolerability of oral paclitaxel (205
mg/m2) with encequidar administered orally, once daily, for 3
consecutive days per week in patients with cutaneous angiosarcoma
(clinicaltrials.gov identifier: NCT03544567).
The abstract title is currently available on the ASCO Meeting
Library, with the full abstract scheduled to be published on May
13, 2020, at 5:00 PM EDT.
The Orascovery platform was initially developed by Hanmi
Pharmaceuticals and licensed exclusively to Athenex for all major
worldwide territories except Korea, which is retained by Hanmi.
About Angiosarcoma Angiosarcomas are a
type of soft tissue sarcoma characterized by rapidly proliferating,
extensively infiltrating, anaplastic cells derived from blood and
lymphatic vessels. Angiosarcomas arise in various body sites,
including cutaneous, soft tissue, and visceral locations.
Angiosarcomas are frequently metastatic at diagnosis, with a
natural history complicated by local recurrence, distant
metastases, and poor overall survival. There is no approved
treatment for angiosarcoma and survival is limited with treatments
currently available. However, reports in the literature of
objective tumor response support the use of intravenous paclitaxel
in the treatment of angiosarcoma.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on P-glycoprotein
inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; multiple locations in Chongqing,
China; Manchester, UK; Guatemala
City, Guatemala and Buenos Aires, Argentina. For
more information, please visit www.athenex.com.
Forward-Looking Statements Except for
historical information, all of the statements, expectations, and
assumptions contained in this press release are forward-looking
statements. These forward-looking statements are typically
identified by terms such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “foresee,” “goal,” “guidance,”
“intend,” “likely,” “may,” “plan,” “potential,” “predict,”
“preliminary,” “probable,” “project,” “promising,” “seek,”
“should,” “will,” “would,” and similar expressions. Actual results
might differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause
actual results to differ materially include: the development stage
of our primary clinical candidates and related risks involved in
drug development, clinical trials, regulation, manufacturing and
commercialization; our reliance on third parties for success in
certain areas of Athenex’s business; our history of operating
losses and need to raise additional capital to continue as a going
concern; risks and uncertainties related to the COVID-19 pandemic
and its potential impact on our operations, cash flow and financial
condition; our ability to integrate CIDAL’s assets into our
existing operations; competition; intellectual property risks;
risks relating to doing business internationally and in China;
the uncertainty of when, if at all, we will be able to resume full
API production operations in Chongqing; and the other risk
factors set forth from time to time in our SEC filings,
copies of which are available for free in the Investor Relations
section of our website
at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or
upon request from our Investor Relations Department. All
information provided in this release is as of the date hereof and
we assume no obligation and do not intend to update these
forward-looking statements, except as required by law.
CONTACTS Investor Relations: Tim McCarthy
Managing Director, LifeSci Advisors, LLC Direct:
212-915-2564
Athenex, Inc.: Randoll Sze Chief Financial Officer
Email: RandollSze@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: JacquelineLi@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024